No profile data available.
Rezolute, Inc. (RZLT) is a healthcare company in the additional hormone and metabolic drugs industry, based in Redwood City, United States, with about 58 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$74.41 million. In Q4 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $471.04 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended June 30, 2025; market data as of October 9, 2026.
, a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States.
Rezolute reported $0 in revenue for fiscal year 2025. In Q4 2026 revenue was $0.
$471.04 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional hormone and metabolic drugs) include MBX Biosciences, Inc. (MBX), Immix Biopharma, Inc. (IMMX), Arbutus Biopharma Corporation (ABUS), Spruce Biosciences, Inc. (SPRB).